Indaptus Therapeutics, Inc. — Form 8-K
Filed September 9, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Indaptus Therapeutics signed a stock purchase agreement dated September 8, 2026, to sell up to $24,000,000 of common stock to multiple offshore purchasers under Regulation S exemption (non-U.S. persons only). Share price = Nasdaq Minimum Price + $0.015. Closing within 15 business days, contingent on Nasdaq approval and any required stockholder vote. Company must register resale shares on Form S-1/S-3 and bear all registration costs. Purchasers limited to <4.99% beneficial ownership.
Why this rating
At $5.8M market cap, a $24M raise is ~4.1x current valuation—transformational if fully subscribed. Massive dilution to existing shareholders but critical for a micro-cap biotech survival and clinical development. Regulation S structure limits immediate liquidity concerns.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $2.08 | +10 min · unknown $2.08 ▲ 0.00% | +30 min · unknown $2.08 ▲ 0.00% | +1 hr · unknown $2.08 ▲ 0.00% | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.